captopril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
angiotensin-converting enzyme inhibitors	484	62571-86-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: captopril (-)-Captopril L-Captopril lopirin S-Captopril SQ14225 SQ-14225 SQ 14225	A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. Molecular weight: 217.28 Formula: C9H15NO3S CLOGP: 0.89 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 57.61 ALOGS: -1.68 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

captopril
(-)-Captopril
L-Captopril
lopirin
S-Captopril
SQ14225
SQ-14225
SQ 14225

A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.

Molecular weight: 217.28
Formula: C9H15NO3S
CLOGP: 0.89
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 57.61
ALOGS: -1.68
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
50	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	160 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	38 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	19.72 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	69 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.75 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	12 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.73 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
April 6, 1981	FDA	PAR PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Segmental diverticular colitis	96.41	14.85	18	11414	156	63477434
Pedal pulse abnormal	95.60	14.85	18	11414	164	63477426
Toxic epidermal necrolysis	86.60	14.85	55	11377	25279	63452311
Calcium ionised decreased	86.10	14.85	18	11414	291	63477299
Blood pressure abnormal	75.50	14.85	42	11390	15156	63462434
Cardiac failure congestive	75.41	14.85	88	11344	92345	63385245
Insulin autoimmune syndrome	70.89	14.85	13	11419	101	63477489
Feeding intolerance	69.65	14.85	18	11414	756	63476834
Reduced facial expression	65.12	14.85	21	11411	1945	63475645
Multiple organ dysfunction syndrome	60.12	14.85	62	11370	56690	63420900
Restlessness	56.60	14.85	45	11387	29408	63448182
Listless	53.72	14.85	20	11412	2840	63474750
Dermatitis exfoliative	53.69	14.85	24	11408	5435	63472155
Head discomfort	50.57	14.85	31	11401	13384	63464206
Self-injurious ideation	47.78	14.85	18	11414	2641	63474949
Labile hypertension	42.27	14.85	11	11421	475	63477115
Left ventricular hypertrophy	41.77	14.85	20	11412	5295	63472295
Myocardial infarction	40.53	14.85	68	11364	99825	63377765
Gastrointestinal sounds abnormal	40.45	14.85	18	11414	4033	63473557
Hyponatraemia	39.96	14.85	72	11360	111828	63365762
Prescription drug used without a prescription	38.73	14.85	15	11417	2371	63475219
Cardiac failure	37.93	14.85	62	11370	89080	63388510
Apathy	37.49	14.85	22	11410	8772	63468818
Electrolyte imbalance	37.13	14.85	30	11402	20046	63457544
Hyperthyroidism	36.12	14.85	26	11406	14647	63462943
Foreign body	35.49	14.85	14	11418	2324	63475266
Dehydration	34.56	14.85	88	11344	173266	63304324
Haemodynamic instability	34.03	14.85	21	11411	9169	63468421
Immobile	33.89	14.85	18	11414	5925	63471665
Drug interaction	33.58	14.85	104	11328	229027	63248563
Cholecystitis	32.80	14.85	25	11407	15352	63462238
Joint swelling	31.36	14.85	10	11422	327656	63149934
Affect lability	30.32	14.85	21	11411	11130	63466460
Hypokalaemia	29.92	14.85	61	11371	103743	63373847
Fatigue	29.21	14.85	74	11358	887954	62589636
Skin test positive	29.15	14.85	9	11423	723	63476867
Renal failure	29.14	14.85	65	11367	117587	63360003
Arthralgia	29.08	14.85	36	11396	569674	62907916
Abdominal discomfort	28.63	14.85	11	11421	320874	63156716
Atrial fibrillation	28.40	14.85	64	11368	116572	63361018
Systemic lupus erythematosus	27.08	14.85	3	11429	208915	63268675
Acute myocardial infarction	26.86	14.85	31	11401	32093	63445497
Cognitive disorder	26.74	14.85	41	11391	55774	63421816
Hypertensive crisis	26.50	14.85	22	11410	15264	63462326
Blood urea increased	26.45	14.85	28	11404	26351	63451239
Hypotension	26.40	14.85	108	11324	272496	63205094
Infusion related reaction	26.29	14.85	6	11426	245515	63232075
Metabolic acidosis	25.78	14.85	36	11396	45033	63432557
Respiratory disorder	25.06	14.85	33	11399	39049	63438541
Cholelithiasis	25.00	14.85	35	11397	43890	63433700
Alopecia	24.88	14.85	15	11417	337521	63140069
Pain	24.88	14.85	61	11371	740567	62737023
Therapeutic product effect decreased	24.48	14.85	3	11429	193184	63284406
Acute kidney injury	23.66	14.85	102	11330	263313	63214277
Circulatory collapse	23.27	14.85	24	11408	21914	63455676
Occupational exposure to product	23.24	14.85	10	11422	2068	63475522
Cross sensitivity reaction	22.85	14.85	10	11422	2152	63475438
Vascular stent thrombosis	22.72	14.85	8	11424	969	63476621
Abnormal behaviour	21.94	14.85	23	11409	21403	63456187
Urinary retention	21.65	14.85	27	11405	30274	63447316
Renal injury	21.58	14.85	16	11416	9423	63468167
Bedridden	21.47	14.85	17	11415	11034	63466556
Hyperkalaemia	20.78	14.85	36	11396	54167	63423423
Off label use	20.76	14.85	58	11374	674404	62803186
Cyanosis	20.68	14.85	20	11412	16915	63460675
Rheumatoid arthritis	20.56	14.85	10	11422	253809	63223781
Contraindicated product administered	20.18	14.85	7	11425	217641	63259949
Sudden death	20.14	14.85	16	11416	10433	63467157
Blood sodium decreased	19.60	14.85	23	11409	24229	63453361
Progressive supranuclear palsy	19.29	14.85	4	11428	62	63477528
Cardiac failure acute	19.25	14.85	15	11417	9508	63468082
Blood creatinine increased	18.96	14.85	46	11386	87798	63389792
Maternal exposure during pregnancy	18.87	14.85	8	11424	220054	63257536
Musculoskeletal stiffness	18.81	14.85	5	11427	184613	63292977
Bradycardia	18.73	14.85	41	11391	73186	63404404
Coronary artery disease	18.72	14.85	26	11406	32351	63445239
Pelvic fracture	18.67	14.85	17	11415	13331	63464259
Elastosis perforans	18.47	14.85	3	11429	10	63477580
Posterior reversible encephalopathy syndrome	18.44	14.85	19	11413	17326	63460264
Nodal rhythm	18.22	14.85	8	11424	1735	63475855
Artery dissection	18.14	14.85	4	11428	84	63477506
Encephalopathy	17.97	14.85	28	11404	38592	63438998
Arthropathy	17.91	14.85	10	11422	234782	63242808
Cerebrovascular accident	17.66	14.85	51	11381	107973	63369617
Blood potassium decreased	17.55	14.85	29	11403	41997	63435593
Lymphocytosis	17.55	14.85	9	11423	2758	63474832
Stevens-Johnson syndrome	17.46	14.85	22	11410	24928	63452662
Extrasystoles	17.12	14.85	11	11421	5149	63472441
Scleroderma renal crisis	17.08	14.85	5	11427	335	63477255
Shock	16.91	14.85	21	11411	23442	63454148
Sinusitis	16.79	14.85	10	11422	226643	63250947
Renal impairment	16.70	14.85	44	11388	88311	63389279
Potentiating drug interaction	16.24	14.85	10	11422	4346	63473244
Angiopathy	15.72	14.85	10	11422	4603	63472987
Nasopharyngitis	15.24	14.85	14	11418	254243	63223347
Occupational dermatitis	14.89	14.85	3	11429	40	63477550
Hepatic enzyme increased	14.88	14.85	9	11423	202319	63275271
Hypoacusis	14.88	14.85	20	11412	24131	63453459

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood ketone body increased	35.55	14.69	10	8385	433	34948103
Cyanosis	32.68	14.69	26	8369	12738	34935798
Angioedema	28.81	14.69	40	8355	37334	34911202
Hypertensive crisis	27.18	14.69	20	8375	8731	34939805
Cardiac failure congestive	27.13	14.69	61	8334	83209	34865327
Scleroderma renal crisis	26.08	14.69	7	8388	254	34948282
Renal failure	24.57	14.69	78	8317	130479	34818057
Kidney small	23.86	14.69	5	8390	60	34948476
Myocardial infarction	23.39	14.69	73	8322	121012	34827524
Cerebrovascular accident	23.15	14.69	58	8337	84753	34863783
Coronary artery disease	22.42	14.69	41	8354	48264	34900272
Blood creatinine increased	20.92	14.69	60	8335	94916	34853620
Long QT syndrome	20.41	14.69	11	8384	2792	34945744
Indifference	19.51	14.69	5	8390	151	34948385
Hypokalaemia	19.34	14.69	43	8352	58171	34890365
Pulmonary hypertensive crisis	19.00	14.69	5	8390	168	34948368
Pulmonary hypoplasia	17.63	14.69	6	8389	491	34948045
Reaction to excipient	17.42	14.69	6	8389	509	34948027
Vitamin B12 deficiency	16.71	14.69	11	8384	4020	34944516
Vascular resistance systemic decreased	16.33	14.69	4	8391	100	34948436
Arrhythmia	16.11	14.69	30	8365	35778	34912758
Renal failure neonatal	15.83	14.69	4	8391	114	34948422
Bronchospasm	15.80	14.69	16	8379	10715	34937821
Drug reaction with eosinophilia and systemic symptoms	15.28	14.69	28	8367	32984	34915552
Cardiac failure	14.90	14.69	52	8343	91196	34857340
Renal impairment	14.70	14.69	53	8342	94460	34854076

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Segmental diverticular colitis	92.96	12.81	18	17372	156	79726842
Pedal pulse abnormal	91.01	12.81	18	17372	176	79726822
Cardiac failure congestive	88.91	12.81	131	17259	142271	79584727
Calcium ionised decreased	71.17	12.81	18	17372	569	79726429
Feeding intolerance	64.35	12.81	18	17372	842	79726156
Myocardial infarction	60.77	12.81	128	17262	184001	79542997
Toxic epidermal necrolysis	58.99	12.81	60	17330	44521	79682477
Insulin autoimmune syndrome	51.15	12.81	13	17377	419	79726579
Reduced facial expression	50.65	12.81	20	17370	2745	79724253
Cyanosis	46.95	12.81	41	17349	25141	79701857
Renal failure	45.88	12.81	121	17269	200847	79526151
Hypertensive crisis	45.27	12.81	37	17353	20733	79706265
Blood pressure abnormal	42.59	12.81	33	17357	17136	79709862
Cardiac failure	42.46	12.81	100	17290	154742	79572256
Self-injurious ideation	42.15	12.81	19	17371	3619	79723379
Head discomfort	40.68	12.81	30	17360	14472	79712526
Multiple organ dysfunction syndrome	40.11	12.81	84	17306	120162	79606836
Labile hypertension	38.85	12.81	11	17379	538	79726460
Cerebrovascular accident	38.01	12.81	96	17294	155196	79571802
Listless	37.97	12.81	18	17372	3843	79723155
Gastrointestinal sounds abnormal	37.71	12.81	20	17370	5415	79721583
Apathy	36.75	12.81	27	17363	12950	79714048
Dermatitis exfoliative	36.37	12.81	25	17365	10804	79716194
Coronary artery disease	36.24	12.81	57	17333	65417	79661581
Restlessness	35.27	12.81	47	17343	46445	79680553
Joint swelling	34.63	12.81	10	17380	288636	79438362
Blood creatinine increased	34.00	12.81	92	17298	154965	79572033
Angioedema	33.80	12.81	60	17330	75975	79651023
Scleroderma renal crisis	33.48	12.81	10	17380	591	79726407
Electrolyte imbalance	32.80	12.81	37	17353	30844	79696154
Off label use	32.72	12.81	96	17294	907119	78819879
Drug interaction	32.41	12.81	177	17213	415006	79311992
Completed suicide	32.41	12.81	7	17383	245760	79481238
Occupational exposure to product	31.98	12.81	10	17380	690	79726308
Hypotension	31.91	12.81	184	17206	440133	79286865
Hyponatraemia	30.80	12.81	97	17293	177751	79549247
Hypokalaemia	29.14	12.81	83	17307	143957	79583041
Prescription drug used without a prescription	28.25	12.81	15	17375	4070	79722928
Blood ketone body increased	27.57	12.81	9	17381	713	79726285
Acute myocardial infarction	27.07	12.81	55	17335	76981	79650017
Foreign body	26.96	12.81	13	17377	2881	79724117
Immobile	25.57	12.81	17	17373	6956	79720042
Renal impairment	25.45	12.81	84	17306	157699	79569299
Pulmonary hypoplasia	24.83	12.81	5	17385	54	79726944
Arthralgia	24.82	12.81	55	17335	571748	79155250
Bradycardia	24.45	12.81	75	17315	135482	79591516
Hyperthyroidism	24.25	12.81	27	17363	22182	79704816
Cholecystitis	24.25	12.81	27	17363	22185	79704813
Cross sensitivity reaction	23.91	12.81	13	17377	3699	79723299
Posterior reversible encephalopathy syndrome	23.77	12.81	29	17361	26252	79700746
Rheumatoid arthritis	23.60	12.81	8	17382	208462	79518536
Skin test positive	23.30	12.81	9	17381	1165	79725833
Abdominal discomfort	23.05	12.81	13	17377	250714	79476284
Fatigue	22.76	12.81	115	17275	929612	78797386
Cholelithiasis	22.69	12.81	41	17349	52623	79674375
Left ventricular hypertrophy	22.44	12.81	19	17371	11172	79715826
Affect lability	22.34	12.81	19	17371	11240	79715758
Respiratory disorder	22.03	12.81	37	17353	44819	79682179
Drug reaction with eosinophilia and systemic symptoms	21.55	12.81	45	17345	64199	79662799
Dehydration	21.52	12.81	109	17281	248078	79478920
Indifference	21.12	12.81	6	17384	297	79726701
Infusion related reaction	21.08	12.81	12	17378	230225	79496773
Renal injury	20.97	12.81	22	17368	16905	79710093
Nasopharyngitis	20.82	12.81	15	17375	253866	79473132
Pulmonary oedema	19.97	12.81	53	17337	88201	79638797
Atrial fibrillation	19.37	12.81	90	17300	197796	79529202
Bedridden	19.23	12.81	18	17372	12061	79714937
Cognitive disorder	18.97	12.81	45	17345	69881	79657117
Alopecia	18.54	12.81	14	17376	231341	79495657
Blood urea increased	18.54	12.81	36	17354	48754	79678244
COVID-19 treatment	18.52	12.81	6	17384	464	79726534
Lower respiratory tract infection	18.48	12.81	3	17387	129217	79597781
Long QT syndrome	18.25	12.81	13	17377	5942	79721056
Ventricular extrasystoles	18.24	12.81	22	17368	19682	79707316
Elastosis perforans	17.67	12.81	3	17387	11	79726987
Arrhythmia	17.24	12.81	40	17350	61232	79665766
Kidney small	17.23	12.81	5	17385	267	79726731
Pelvic fracture	17.19	12.81	17	17373	12187	79714811
Haemodynamic instability	17.06	12.81	20	17370	17362	79709636
Hypertension	17.03	12.81	127	17263	330865	79396133
Blood potassium increased	16.91	12.81	26	17364	29249	79697749
Oligohydramnios	16.73	12.81	10	17380	3402	79723596
Laryngeal oedema	16.71	12.81	14	17376	8115	79718883
Tongue oedema	16.19	12.81	13	17377	7104	79719894
Pain	16.10	12.81	89	17301	703713	79023285
Blood potassium decreased	16.09	12.81	33	17357	46479	79680519
Hyperplasia	16.03	12.81	7	17383	1236	79725762
Stomatitis	15.98	12.81	6	17384	146751	79580247
Wound	15.95	12.81	3	17387	116176	79610822
Hyperkalaemia	15.91	12.81	58	17332	114340	79612658
Progressive supranuclear palsy	15.89	12.81	4	17386	124	79726874
Pulmonary hypertensive crisis	15.85	12.81	5	17385	355	79726643
Circulatory collapse	15.81	12.81	29	17361	37639	79689359
Therapeutic product effect decreased	15.78	12.81	8	17382	163855	79563143
Extrasystoles	15.71	12.81	13	17377	7406	79719592
Cardiac failure acute	15.69	12.81	20	17370	18909	79708089
Drug ineffective	15.51	12.81	156	17234	1080757	78646241
Congenital anomaly	15.51	12.81	5	17385	381	79726617
Klebsiella infection	15.29	12.81	18	17372	15702	79711296
Shock	15.19	12.81	31	17359	43517	79683481
Haemorrhagic necrotic pancreatitis	15.03	12.81	4	17386	155	79726843
Nodal rhythm	14.88	12.81	9	17381	3126	79723872
Musculoskeletal stiffness	14.79	12.81	10	17380	174998	79552000
Lactic acidosis	14.66	12.81	41	17349	70318	79656680
Scleroedema	14.46	12.81	3	17387	38	79726960
Sinusitis	14.22	12.81	13	17377	195488	79531510
Pulmonary hypertension	14.20	12.81	32	17358	48048	79678950
Maternal exposure during pregnancy	14.18	12.81	6	17384	136532	79590466
Angiopathy	14.15	12.81	12	17378	7070	79719928
Vascular resistance systemic decreased	13.65	12.81	4	17386	221	79726777
Cardio-respiratory arrest	13.43	12.81	53	17337	108457	79618541
Rhabdomyolysis	13.27	12.81	51	17339	103080	79623918
Rhythm idioventricular	13.16	12.81	5	17385	619	79726379
Apraxia	13.02	12.81	8	17382	2859	79724139
Injection site pain	13.02	12.81	6	17384	129832	79597166
Acute interstitial pneumonitis	12.95	12.81	6	17384	1217	79725781
Artery dissection	12.82	12.81	4	17386	274	79726724

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C09AA01	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, PLAIN ACE inhibitors, plain
ATC	C09BA01	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and diuretics
FDA MoA	N0000000181	Angiotensin-converting Enzyme Inhibitors
FDA EPC	N0000175562	Angiotensin Converting Enzyme Inhibitor
CHEBI has role	CHEBI:35457	ACE inhibitor
CHEBI has role	CHEBI:35674	antihypertensive drugs
MeSH PA	D000806	Angiotensin-Converting Enzyme Inhibitors
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011480	Protease Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Chronic heart failure	indication	48447003
Diabetic renal disease	indication	127013003
Left ventricular cardiac dysfunction	indication	429589006
Atrial fibrillation	off-label use	49436004	DOID:0060224
Cystinuria	off-label use	85020001	DOID:9266
Diastolic heart failure	off-label use	418304008	DOID:9775
Cystine Renal Calculi	off-label use
Nondiabetic Proteinuric Nephropathy	off-label use
Anuria	contraindication	2472002	DOID:2983
Hypercholesterolemia	contraindication	13644009
Hyperkalemia	contraindication	14140009
Secondary angle-closure glaucoma	contraindication	21571006
Hypovolemia	contraindication	28560003
Acute cerebrovascular insufficiency	contraindication	29322000
Dehydration	contraindication	34095006
Hyperuricemia	contraindication	35885006	DOID:1920
Immunosuppression	contraindication	38013005
Angioedema	contraindication	41291007	DOID:1558
Hypokalemia	contraindication	43339004
Low blood pressure	contraindication	45007003
Cough	contraindication	49727002
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Aortic valve stenosis	contraindication	60573004	DOID:1712
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Hypochloremic alkalosis	contraindication	70134007
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Transplantation	contraindication	77465005
Hereditary angioneurotic edema	contraindication	82966003	DOID:14735
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Disorder of connective tissue	contraindication	105969002	DOID:65
Hypomagnesemia	contraindication	190855004
Acute pancreatitis	contraindication	197456007	DOID:2913
Hypertrophic cardiomyopathy	contraindication	233873004	DOID:11984
Disease of liver	contraindication	235856003	DOID:409
Neonatal hyperbilirubinemia	contraindication	281610001
Pregnancy, function	contraindication	289908002
Renal artery stenosis	contraindication	302233006
Neutropenic disorder	contraindication	303011007	DOID:1227
Bone marrow depression	contraindication	307762000
Azotemia	contraindication	445009001
Hemodialysis with High-Flux Membrane	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.85	acidic
pKa2	9.56	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Angiotensin-converting enzyme	Enzyme	P12821	ACE_HUMAN	INHIBITOR	Ki	8.70	WOMBAT-PK	CHEMBL
Prostaglandin G/H synthase 1	Enzyme	P23219	PGH1_HUMAN		Ki	4.77	CHEMBL
Prothrombin	Enzyme	P00734	THRB_HUMAN		Ki	7.32	CHEMBL
Renin	Enzyme	P00797	RENI_HUMAN		Ki	8.77	CHEMBL
Leukotriene A-4 hydrolase	Enzyme	P09960	LKHA4_HUMAN		IC50	7.15	CHEMBL
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN		Ki	4.92	CHEMBL
Angiotensin-converting enzyme	Enzyme		ACE_RABIT		Ki	8.77	CHEMBL
Angiotensin-converting enzyme	Enzyme		ACE_RAT		Ki	8.70	CHEMBL
Succinyl-diaminopimelate desuccinylase	Enzyme		DAPE_HAEIN		Ki	5.74	CHEMBL
Beta-lactamase	Enzyme		Q79MP6_PSEAI		Ki	5.62	CHEMBL
Beta-lactamase II	Enzyme		Q93T40_BACAN		Ki	4.75	CHEMBL
Beta-lactamase class B VIM-2	Unclassified		Q9K2N0_PSEAI		Kd	6.22	CHEMBL
Beta-lactamase NDM-1	Enzyme		BLAN1_KLEPN		Kd	4.85	CHEMBL

External reference:

ID	Source
4017614	VUID
N0000145994	NUI
D00251	KEGG_DRUG
1998	RXNORM
C0006938	UMLSCUI
CHEBI:3380	CHEBI
X8Z	PDB_CHEM_ID
CHEMBL1560	ChEMBL_ID
DB01197	DRUGBANK_ID
D002216	MESH_DESCRIPTOR_UI
44093	PUBCHEM_CID
5158	IUPHAR_LIGAND_ID
4373	INN_ID
9G64RSX1XD	UNII
4347	MMSL
455	MMSL
d00006	MMSL
29439004	SNOMEDCT_US
387160004	SNOMEDCT_US
4017614	VANDF
000656	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1171	TABLET	12.50 mg	ORAL	ANDA	22 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1171	TABLET	12.50 mg	ORAL	ANDA	22 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1172	TABLET	25 mg	ORAL	ANDA	22 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1172	TABLET	25 mg	ORAL	ANDA	22 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1173	TABLET	50 mg	ORAL	ANDA	22 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1173	TABLET	50 mg	ORAL	ANDA	22 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1174	TABLET	100 mg	ORAL	ANDA	22 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1174	TABLET	100 mg	ORAL	ANDA	22 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0615-4519	TABLET	12.50 mg	ORAL	ANDA	21 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0615-4520	TABLET	25 mg	ORAL	ANDA	21 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0615-4521	TABLET	50 mg	ORAL	ANDA	21 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8052	TABLET	12.50 mg	ORAL	ANDA	16 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8061	TABLET	25 mg	ORAL	ANDA	16 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8075	TABLET	50 mg	ORAL	ANDA	16 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8080	TABLET	100 mg	ORAL	ANDA	16 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0904-5045	TABLET	12.50 mg	ORAL	ANDA	22 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0904-5046	TABLET	25 mg	ORAL	ANDA	22 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0904-5047	TABLET	50 mg	ORAL	ANDA	22 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7105	TABLET	12.50 mg	ORAL	ANDA	12 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7106	TABLET	25 mg	ORAL	ANDA	12 sections
CAPTOPRIL	HUMAN PRESCRIPTION DRUG LABEL	1	10544-175	TABLET	50 mg	ORAL	ANDA	19 sections
CAPTOPRIL AND HYDROCHLOROTHIAZIDE	Human Prescription Drug Label	2	16571-827	TABLET	25 mg	ORAL	ANDA	22 sections
CAPTOPRIL AND HYDROCHLOROTHIAZIDE	Human Prescription Drug Label	2	16571-828	TABLET	25 mg	ORAL	ANDA	22 sections
CAPTOPRIL AND HYDROCHLOROTHIAZIDE	Human Prescription Drug Label	2	16571-829	TABLET	50 mg	ORAL	ANDA	22 sections
CAPTOPRIL AND HYDROCHLOROTHIAZIDE	Human Prescription Drug Label	2	16571-830	TABLET	50 mg	ORAL	ANDA	22 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	21695-477	TABLET	25 mg	ORAL	ANDA	24 sections
Captopril	HUMAN PRESCRIPTION DRUG LABEL	1	21695-478	TABLET	50 mg	ORAL	ANDA	24 sections
Captopril	Human Prescription Drug Label	1	27241-160	TABLET	12.50 mg	ORAL	ANDA	12 sections
Captopril	Human Prescription Drug Label	1	27241-161	TABLET	25 mg	ORAL	ANDA	12 sections
Captopril	Human Prescription Drug Label	1	27241-162	TABLET	50 mg	ORAL	ANDA	12 sections